Zhang M, Han Z, Lin Y, Jin Z, Zhou S, Wang S
Front Microbiol. 2024; 15:1418301.
PMID: 39006752
PMC: 11239345.
DOI: 10.3389/fmicb.2024.1418301.
Yang F, Luo J
Front Cell Infect Microbiol. 2024; 14:1401323.
PMID: 38895738
PMC: 11183278.
DOI: 10.3389/fcimb.2024.1401323.
Horbal S, Belancourt P, Zhang P, Holcombe S, Saini S, Wang S
Dig Dis Sci. 2024; 69(7):2681-2690.
PMID: 38653948
PMC: 11258161.
DOI: 10.1007/s10620-024-08450-5.
Cheng P, Chen W, Hou C, Lin C, Chang M, Wang C
Clin Mol Hepatol. 2023; 30(1):16-36.
PMID: 37793641
PMC: 10776290.
DOI: 10.3350/cmh.2023.0315.
Wang W, Chen C, Lo Re 3rd V, Chang S, Wilson D, Park H
Pharmacoepidemiol Drug Saf. 2023; 32(10):1142-1151.
PMID: 37278688
PMC: 10655016.
DOI: 10.1002/pds.5651.
Hepatitis Virus C-associated Nephropathy: A Review and Update.
Habas Sr E, Farfar K, Errayes N, Habas A, Errayes M, Alfitori G
Cureus. 2022; 14(7):e27322.
PMID: 36043014
PMC: 9412079.
DOI: 10.7759/cureus.27322.
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort.
Calvaruso V, Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Distefano M
J Viral Hepat. 2021; 28(8):1190-1199.
PMID: 33896097
PMC: 8359835.
DOI: 10.1111/jvh.13523.
Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.
Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R
Adv Exp Med Biol. 2020; 1323:115-147.
PMID: 33326112
DOI: 10.1007/5584_2020_604.
Short- and long-term outcomes following percutaneous coronary intervention in hepatitis C virus seropositive patients.
Hussein A, Abdel Ghany M, Mahmoud H
Egypt Heart J. 2020; 72(1):44.
PMID: 32712829
PMC: 7382666.
DOI: 10.1186/s43044-020-00079-9.
HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.
Cooper C, Galanakis C, Donelle J, Kwong J, Boyd R, Boucher L
BMC Infect Dis. 2019; 19(1):712.
PMID: 31438873
PMC: 6706878.
DOI: 10.1186/s12879-019-4315-6.
Hepatitis C virus and the kidney.
Pol S, Parlati L, Jadoul M
Nat Rev Nephrol. 2018; 15(2):73-86.
PMID: 30455426
DOI: 10.1038/s41581-018-0081-8.
Impact of hepatitis C virus infection on long-term mortality after acute myocardial infarction: a nationwide population-based, propensity-matched cohort study in Taiwan.
Kuo S, Hung W, Tang P, Huang W, Yang J, Lin H
BMJ Open. 2018; 8(1):e017412.
PMID: 29374659
PMC: 5829782.
DOI: 10.1136/bmjopen-2017-017412.
Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction.
Pasarin M, Abraldes J, Liguori E, Kok B, La Mura V
World J Gastroenterol. 2017; 23(37):6777-6787.
PMID: 29085222
PMC: 5645612.
DOI: 10.3748/wjg.v23.i37.6777.
Subclinical myocardial disease by cardiac magnetic resonance imaging and spectroscopy in healthy HIV/Hepatitis C virus-coinfected persons.
Chew K, Liu C, Ambale-Venkatesh B, Liao D, Horwich T, Lima J
J Int Med Res. 2017; 45(6):1693-1707.
PMID: 28606026
PMC: 5805202.
DOI: 10.1177/0300060517708919.
Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons.
Chew K, Bhattacharya D, Horwich T, Yan P, McGinnis K, Tseng C
J Viral Hepat. 2017; 24(10):814-822.
PMID: 28273386
PMC: 5589479.
DOI: 10.1111/jvh.12705.
Hepatitis C virus and cardiovascular: A review.
Petta S
J Adv Res. 2017; 8(2):161-168.
PMID: 28149651
PMC: 5272956.
DOI: 10.1016/j.jare.2016.06.001.
Hepatitis B virus infection and risk of coronary artery disease: a meta-analysis.
Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P
Ann Transl Med. 2016; 4(21):423.
PMID: 27942514
PMC: 5124622.
DOI: 10.21037/atm.2016.11.12.
Anti-hepatitis C virus drugs and kidney.
Carrier P, Essig M, Debette-Gratien M, Sautereau D, Rousseau A, Marquet P
World J Hepatol. 2016; 8(32):1343-1353.
PMID: 27917261
PMC: 5114471.
DOI: 10.4254/wjh.v8.i32.1343.
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S, Prosperi M, Costarelli S, Nasta P, Maggiolo F, Di Giambenedetto S
Eur J Clin Microbiol Infect Dis. 2016; 35(9):1511-20.
PMID: 27272121
DOI: 10.1007/s10096-016-2692-y.
Viral hepatitis: Drug-drug interactions in HCV treatment--the good, the bad and the ugly.
Langness J, Everson G
Nat Rev Gastroenterol Hepatol. 2016; 13(4):194-5.
PMID: 26882885
DOI: 10.1038/nrgastro.2016.24.
